Silencing MRP4 by small interfering RNA reverses acquired DDP resistance of gastric cancer cell

Cancer Letters

Volumn 291, Issue 1, 2010, Pages 76-82

  Zhang, Yan Hong ^a   Wu, Qing ^b   Xiao, Xiu Ying ^a   Li, Da Wei ^b   Wang, Xing Peng ^c  

^a SHANGHAI XUHUI CENTRAL HOSPITAL   (China)

^b SHANGHAI JIAO TONG UNIVERSITY   (China)

^c TONGJI UNIVERSITY   (China)

Author keywords

Chemotherapy; DDP; Gastric cancer; MRP4; Multi drug resistance

Indexed keywords

CISPLATIN; MESSENGER RNA; MULTIDRUG RESISTANCE PROTEIN 4; SMALL INTERFERING RNA;

ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; GENE CONTROL; GENE EXPRESSION REGULATION; GENE IDENTIFICATION; GENE SILENCING; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; NUCLEOTIDE SEQUENCE; PHARMACOGENETICS; PHENOTYPE; PRIORITY JOURNAL; RNA INTERFERENCE; STOMACH CANCER; UPREGULATION;

ANTINEOPLASTIC AGENTS; APOPTOSIS; BASE SEQUENCE; CELL LINE, TUMOR; CISPLATIN; DRUG RESISTANCE, NEOPLASM; GENE EXPRESSION PROFILING; HUMANS; MOLECULAR SEQUENCE DATA; MULTIDRUG RESISTANCE-ASSOCIATED PROTEINS; RNA, SMALL INTERFERING; STOMACH NEOPLASMS;

EID: 77949873242     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.canlet.2009.10.003     Document Type: Article

References (28)

1. Nishiyama M. Chemotherapy for gastric cancer in Japan. Int. J. Clin. Oncol. 13 (2008) 191-192
2. K. Nasseri, P.K. Mills, M. Allan, Cancer incidence in the Middle Eastern population of California 1988-2004, Asian Pac. J. Cancer Prev. 8 (2007) 405-411.
3. McCracken M., Olsen M., Chen Jr. M.S., Jemal A., Thun M., Cokkinides V., et al. Cancer incidence, mortality, and associated risk factors among Asian Americans of Chinese, Filipino, Vietnamese, Korean, and Japanese ethnicities. CA Cancer J. Clin. 57 (2007) 190-205
4. Zhou Y., Zhang Z., Zhang Z., Wu J., Ren D., Yan X., et al. A rising trend of gastric cardia cancer in Gansu province of China. Cancer Lett. 269 (2008) 18-25
5. Panani A.D. Cytogenetic and molecular aspects of gastric cancer: clinical implications. Cancer Lett. 266 (2008) 99-115
6. Wu A., and Ji J. Adjuvant chemotherapy for gastric cancer or not: a dilemma?. J. Natl. Cancer Inst. 100 (2008) 376-377
7. Chung Y.M., Park S., Park J.K., Kim Y., Kang Y., and Yoo Y.D. Establishment and characterization of 5-fluorouracil-resistant gastric cancer cells. Cancer Lett. 159 (2000) 95-101
8. Wilson T.R., Longley D.B., and Johnston P.G. Chemoresistance in solid tumours. Ann. Oncol. 17 Suppl. 10 (2006) 315-324
9. Muggia F. Platinum compounds 30 years after the introduction of cisplatin: implications for the treatment of ovarian cancer. Gynecol. Oncol. 112 (2009) 275-281
10. Yanglin P., Lina Z., Zhiguo L., Na L., Haifeng J., Guoyun Z., et al. KCNE2, a down-regulated gene identified by in silico analysis, suppressed proliferation of gastric cancer cells. Cancer Lett. 246 (2007) 129-138
11. Chen L., Chen D., Gong M., Na M., Li L., Wu H., et al. Concomitant use of Ad5/35 chimeric oncolytic adenovirus with TRAIL gene and taxol produces synergistic cytotoxicity in gastric cancer cells. Cancer Lett. 284 (2009) 141-148
12. Nakamura T., Kuwai T., Kitadai Y., Sasaki T., Fan D., Coombes K.R., et al. Zonal heterogeneity for gene expression in human pancreatic carcinoma. Cancer Res. 67 (2007) 7597-7604
13. Chu E.C., Chai J., Ahluwalia A., and Tarnawski A.S. Mesalazine downregulates c-Myc in human colon cancer cells. A key to its chemopreventive action?. Aliment Pharmacol. Ther. 25 (2007) 1443-1449
14. Borst P., Rottenberg S., and Jonkers J. How do real tumors become resistant to cisplatin?. Cell Cycle 7 (2008) 1353-1359
15. Zisowsky J., Koegel S., Leyers S., Devarakonda K., Kassack M.U., Osmak M., et al. Relevance of drug uptake and efflux for cisplatin sensitivity of tumor cells. Biochem. Pharmacol. 73 (2007) 298-307
16. Safaei R., and Howell S.B. Copper transporters regulate the cellular pharmacology and sensitivity to Pt drugs. Crit. Rev. Oncol. Hematol. 53 (2005) 13-23
17. Kitada N., Takara K., Minegaki T., Itoh C., Tsujimoto M., Sakaeda T., et al. Factors affecting sensitivity to antitumor platinum derivatives of human colorectal tumor cell lines. Cancer Chemother. Pharmacol. 62 (2008) 577-584
18. Zhang S., Lovejoy K.S., Shima J.E., Lagpacan L.L., Shu Y., Lapuk A., et al. Organic cation transporters are determinants of oxaliplatin cytotoxicity. Cancer Res. 66 (2006) 8847-8857
19. Yonezawa A., Masuda S., Yokoo S., Katsura T., and Inui K. Cisplatin and oxaliplatin but not carboplatin and nedaplatin are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 319 (2006) 879-886
20. Borst P., Evers R., Kool M., and Wijnholds J. A family of drug transporters: the multidrug resistance-associated proteins. J. Natl. Cancer Inst. 92 (2000) 1295-1302
21. Lee K., Klein-Szanto A.J., and Kruh G.D. Analysis of the MRP4 drug resistance profile in transfected NIH3T3 cells. J. Natl. Cancer Inst. 92 (2000) 1934-1940
22. Tian Q., Zhang J., Tan T.M., Chan E., Duan W., Chan S.Y., et al. Human multidrug resistance associated protein 4 confers resistance to camptothecins. Pharm. Res. 22 (2005) 1837-1853
23. Chen C., and Klaassen C.D. Rat multidrug resistance protein 4 (Mrp4, Abcc4): molecular cloning, organ distribution, postnatal renal expression, and chemical inducibility. Biochem. Biophys. Res. Commun. 317 (2004) 46-53
24. Janke D., Mehralivand S., Strand D., Godtel-Armbrust U., Habermeier A., Gradhand U., et al. 6-Mercaptopurine and 9-(2-phosphonyl-methoxyethyl) adenine (PMEA) transport altered by two missense mutations in the drug transporter gene ABCC4. Hum. Mutat. 29 (2008) 659-669
25. Ho L.L., Kench J.G., Handelsman D.J., Scheffer G.L., Stricker P.D., Grygiel J.G., et al. Androgen regulation of multidrug resistance-associated protein 4 (MRP4/ABCC4) in prostate cancer. Prostate 68 (2008) 1421-1429
26. Norris M.D., Smith J., Tanabe K., Tobin P., Flemming C., Scheffer G.L., et al. Expression of multidrug transporter MRP4/ABCC4 is a marker of poor prognosis in neuroblastoma and confers resistance to irinotecan in vitro. Mol. Cancer Ther. 4 (2005) 547-553
27. El-Sheikh A.A., van den Heuvel J.J., Koenderink J.B., and Russel F.G. Interaction of nonsteroidal anti-inflammatory drugs with multidrug resistance protein (MRP) 2/ABCC2- and MRP4/ABCC4-mediated methotrexate transport. J. Pharmacol. Exp. Ther. 320 (2007) 229-235
28. Wu C.P., Calcagno A.M., Hladky S.B., Ambudkar S.V., and Barrand M.A. Modulatory effects of plant phenols on human multidrug-resistance proteins 1, 4 and 5 (ABCC1, 4 and 5). FEBS J. 272 (2005) 4725-4740